Medplus Health Q1 FY27 Revenue Grows 21.8% to ₹18,796 Million; EBITDA Declines
Medplus Health Services reported Q1 FY27 revenue of ₹18,796 million, a 21.8% YoY increase. The company added 146 new stores. However, Operating EBITDA decreased by 10.6% YoY to ₹651 million, and Operating EBITDA margin fell to 3.5%. Diagnostics revenue grew 22.4% YoY.
The revenue growth is positive, but the decrease in profitability metrics like EBITDA and margins suggests a moderate impact on investor sentiment and future outlook.
While revenue showed strong growth, the decline in EBITDA and margins indicates a mixed performance, leading to a neutral sentiment.
Medplus Health Services Limited announced its un-audited financial results for the quarter ended June 30, 2026. The company reported a revenue growth of 21.8% year-on-year, increasing from ₹15,426 million in Q1 FY26 to ₹18,796 million in Q1 FY27. This growth was accompanied by the addition of 146 new stores during the quarter, including 131 new franchisees.
However, the company experienced a decline in profitability metrics. Gross margin decreased by 160 basis points year-on-year, from 26.1% in Q1 FY26 to 24.5% in Q1 FY27. Operating EBITDA also saw a decrease, falling from ₹728 million in Q1 FY26 to ₹651 million in Q1 FY27. Consequently, the Operating EBITDA margin for Q1 FY27 decreased by 120 basis points year-on-year, from 4.7% to 3.5%.
The company's performance against its Annual Operating Plan (AOP) showed a revenue achievement of 99.0% (₹18,796 million vs. ₹18,993 million AOP) and an Operating EBITDA achievement of 81.6% (₹651 million vs. ₹798 million AOP).
In the Pharmacy segment, revenue grew by 21.8% YoY and 0.7% QoQ. The gross margin percentage decreased by 170 bps YoY and 210 bps QoQ. Operating EBITDA margin for the Pharmacy segment decreased by 140 bps YoY and 240 bps QoQ.
The Diagnostics segment reported a revenue growth of 22.4% YoY and 6.6% QoQ, with Center Level EBITDA increasing by 32.1% YoY and Operating EBITDA showing a significant jump of 59.5% YoY. The company's network expanded to 5,476 pharmacies as of June 30, 2026, with a net addition of 146 stores in Q1 FY27.
Medplus Health Services Limited also informed about the upcoming Earnings Call with Analysts/Institutional Investors scheduled for Wednesday, July 22, 2026, at 16:00 Hrs (IST) to discuss the Un-audited Financial Results for the quarter ended June 30, 2026.
What to do with a filing like this
Medplus Health Services Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it medium impact: worth reading, rarely worth acting on by itself.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Medplus Health Services Limited. Read the original for the full detail.